Piprazon 2.25 Injection is a potent combination of Piperacillin (2000mg), a broad-spectrum penicillin antibiotic, and Tazobactam (250mg), a beta-lactamase inhibitor. This formulation is designed to treat a wide range of severe bacterial infections, including those caused by resistant pathogens.
Piperacillin works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Tazobactam complements this action by neutralizing beta-lactamase enzymes produced by certain bacteria, which would otherwise degrade Piperacillin. This combination extends the spectrum of activity, making it effective against Gram-positive, Gram-negative, and anaerobic bacteria.
Piprazon 2.25 Injection is particularly useful in managing complicated infections such as hospital-acquired pneumonia, intra-abdominal infections, sepsis, skin and soft tissue infections, and complicated urinary tract infections. It is also suitable for treating polymicrobial infections and is often used as empiric therapy in critically ill patients.
This medication is administered via intravenous infusion, ensuring rapid absorption and targeted action. It is typically prescribed in a hospital setting under strict medical supervision to monitor therapeutic efficacy and manage any potential adverse reactions.